Skip to content

Exposomics study on the application of intraviteral injection of anti-VEGF drugs for the treatment of ROP

Exposomics study on the application of intraviteral injection of anti-VEGF drugs for the treatment of ROP

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500109575
Enrollment
Unknown
Registered
2025-09-22
Start date
2025-10-01
Completion date
Unknown
Last updated
2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinopathy of Prematuity

Interventions

observation group:None

Sponsors

The Second Affliated Hospital of Harbin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
0.1 Years to 1 Years

Inclusion criteria

Inclusion criteria: 1. Infants weighing less than 1500g diagnosed with Type I Retinopathy of Prematurity (ROP) by two experienced ophthalmologists require anti-VEGF treatment. This includes cases such as Zone I Stage 1+, Zone I Stage 2+, Zone I Stage 3+, Zone I Stage 3, Zone II Stage 2+, Zone II Stage 3+, and aggressive posterior ROP ; 2. Family members of the infants must be willing to sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Infectious diseases such as HIV, syphilis, hepatitis, or cytomegalovirus infection. 2. Major systemic diseases, such as congenital metabolic disorders or hematologic diseases. 3. Other ocular abnormalities, including congenital cataracts, glaucoma, or defects. 4. Major systemic malformations. 5. Coagulation disorders or medications that may affect metabolic status.

Design outcomes

Primary

MeasureTime frame
plasma metabolities;Cure rate of retinopathy of prematurity;

Countries

China

Contacts

Public ContactZhongyu Zhang

The Second Affliated Hospital of Harbin Medical University

1971714018@qq.com+86 183 0458 0115

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026